Encapsulating Peritoneal Sclerosis

被引：21

作者：

Alston, Helen ^{[1
]}

Fan, Stanley ^{[1
]}

Nakayama, Masaaki ^{[2
]}

机构：

[1] Barts Hlth NHS Trust, Dept Renal Med & Transplantat, London, England

[2] Fukushima Med Univ, Sch Med, Dept Hypertens & Nephrol, Fukushima, Japan

来源：

SEMINARS IN NEPHROLOGY | 2017年 / 37卷 / 01期

关键词：

Encapsulating peritoneal sclerosis; peritoneal membrane; peritoneal dialysis; EPS; GLYCATION END-PRODUCTS; GLUCOSE DEGRADATION-PRODUCTS; DIALYSIS PATIENTS; CLINICAL-PRACTICE; RISK-FACTORS; TAMOXIFEN THERAPY; RENAL-DISEASE; SINGLE-CENTER; NEUTRAL-PH; DUTCH EPS;

D O I：

10.1016/j.semnephrol.2016.10.010

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis. In this review, we describe the clinical picture and histologic changes to the peritoneal membrane that are associated with EPS and provide an update on current diagnosis and management. We also discuss the recent studies that have suggested that the use of more biocompatible solutions containing lower concentrations of glucose degradation product that often are pH neutral in combination with a change in clinical practice (reducing glucose exposure and monitoring peritoneal membrane function) might ameliorate peritoneal degeneration, reduce the incidence of EPS, and minimize the severity of the disease. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：93 / 102

页数：10

共 80 条

[1] Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients:: Pathologic significance and potential therapeutic interventions [J].

Aroeira, Luiz S. ;

Aguilera, Abelardo ;

Sanchez-Tomero, Jose A. ;

Bajo, M. Auxiliadora ;

del Peso, Gloria ;

Jimenez-Heffernan, Jose A. ;

Selgas, Rafael ;

Lopez-Cabrera, Manuel .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :2004-2013

[2] Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications [J].

Augustine, T. ;

Brown, P. W. ;

Davies, S. D. ;

Summers, A. M. ;

Wilkie, M. E. .

NEPHRON CLINICAL PRACTICE, 2009, 111 (02) :C149-C154

[3] PERITONEAL MORPHOLOGY AFTER LONG-TERM PERITONEAL DIALYSIS WITH BIOCOMPATIBLE FLUID: RECENT CLINICAL PRACTICE IN JAPAN [J].

Ayuzawa, Nobuhiro ;

Ishibashi, Yoshitaka ;

Takazawa, Yutaka ;

Kume, Haruki ;

Fujita, Toshiro .

PERITONEAL DIALYSIS INTERNATIONAL, 2012, 32 (02) :159-167

[4] The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis [J].

Balasubramaniam, Gowrie ;

Brown, Edwina A. ;

Davenport, Andrew ;

Cairns, Hugh ;

Cooper, Barbara ;

Fan, Stanley L. S. ;

Farrington, Ken ;

Gallagher, Hugh ;

Harnett, Patrick ;

Krausze, Sally ;

Steddon, Simon .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (10) :3209-3215

[5]

Bansal Saurabh, 2010, Adv Perit Dial, V26, P75

[6] CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONS ON PERITONEAL DIALYSIS ADEQUACY 2011 [J].

Blake, Peter G. ;

Bargman, Joanne M. ;

Brimble, K. Scott ;

Davison, Sara N. ;

Hirsch, David ;

McCormick, Brendan B. ;

Suri, Rita S. ;

Taylor, Paul ;

Zalunardo, Nadia ;

Tonelli, Marcello .

PERITONEAL DIALYSIS INTERNATIONAL, 2011, 31 (02) :218-239

[7] Integrated end-stage renal disease care: the role of peritoneal dialysis [J].

Blake, PG .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 :61-66

[8]

Brown EA, 2009, PERITON DIALYSIS INT, V29, P595

[9] Encapsulating Peritoneal Sclerosis in the New Millennium: A National Cohort Study [J].

Brown, Michaela C. ;

Simpson, Keith ;

Kerssens, Jan J. ;

Mactier, Robert A. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (07) :1222-1229

[10] The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients [J].

Cho, Yeoungjee ;

Johnson, David W. ;

Badve, Sunil V. ;

Craig, Jonathan C. ;

Strippoli, Giovanni F. M. ;

Wiggins, Kathryn J. .

KIDNEY INTERNATIONAL, 2013, 84 (05) :969-979

← 1 2 3 4 5 6 7 8 →